SLDB
Price
$4.54
Change
+$0.29 (+6.82%)
Updated
Jun 6 closing price
Capitalization
351.92M
URGN
Price
$7.37
Change
+$2.23 (+43.39%)
Updated
Jun 6 closing price
Capitalization
339.81M
71 days until earnings call
Interact to see
Advertisement

SLDB vs URGN

Header iconSLDB vs URGN Comparison
Open Charts SLDB vs URGNBanner chart's image
Solid Biosciences
Price$4.54
Change+$0.29 (+6.82%)
Volume$1.61M
Capitalization351.92M
UroGen Pharma
Price$7.37
Change+$2.23 (+43.39%)
Volume$20.72M
Capitalization339.81M
SLDB vs URGN Comparison Chart
Loading...
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SLDB vs. URGN commentary
Jun 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SLDB is a StrongBuy and URGN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 09, 2025
Stock price -- (SLDB: $3.26 vs. URGN: $4.05)
Brand notoriety: SLDB and URGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SLDB: 75% vs. URGN: 131%
Market capitalization -- SLDB: $351.92M vs. URGN: $339.81M
SLDB [@Biotechnology] is valued at $351.92M. URGN’s [@Biotechnology] market capitalization is $339.81M. The market cap for tickers in the [@Biotechnology] industry ranges from $334.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SLDB’s FA Score shows that 2 FA rating(s) are green whileURGN’s FA Score has 0 green FA rating(s).

  • SLDB’s FA Score: 2 green, 3 red.
  • URGN’s FA Score: 0 green, 5 red.
According to our system of comparison, SLDB is a better buy in the long-term than URGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SLDB’s TA Score shows that 3 TA indicator(s) are bullish while URGN’s TA Score has 5 bullish TA indicator(s).

  • SLDB’s TA Score: 3 bullish, 5 bearish.
  • URGN’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, URGN is a better buy in the short-term than SLDB.

Price Growth

SLDB (@Biotechnology) experienced а +20.74% price change this week, while URGN (@Biotechnology) price change was -2.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

URGN is expected to report earnings on Aug 19, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SLDB($352M) and URGN($340M) have the same market capitalization . SLDB YTD gains are higher at: -18.500 vs. URGN (-61.972). URGN has higher annual earnings (EBITDA): -110.34M vs. SLDB (-121.9M). URGN has more cash in the bank: 237M vs. SLDB (149M). SLDB has less debt than URGN: SLDB (24.2M) vs URGN (123M). URGN has higher revenues than SLDB: URGN (90.4M) vs SLDB (0).
SLDBURGNSLDB / URGN
Capitalization352M340M104%
EBITDA-121.9M-110.34M110%
Gain YTD-18.500-61.97230%
P/E RatioN/AN/A-
Revenue090.4M-
Total Cash149M237M63%
Total Debt24.2M123M20%
FUNDAMENTALS RATINGS
SLDB vs URGN: Fundamental Ratings
SLDB
URGN
OUTLOOK RATING
1..100
1154
VALUATION
overvalued / fair valued / undervalued
1..100
20
Undervalued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
9197
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLDB's Valuation (20) in the Biotechnology industry is somewhat better than the same rating for URGN (74). This means that SLDB’s stock grew somewhat faster than URGN’s over the last 12 months.

SLDB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as URGN (100). This means that SLDB’s stock grew similarly to URGN’s over the last 12 months.

SLDB's SMR Rating (98) in the Biotechnology industry is in the same range as URGN (100). This means that SLDB’s stock grew similarly to URGN’s over the last 12 months.

SLDB's Price Growth Rating (91) in the Biotechnology industry is in the same range as URGN (97). This means that SLDB’s stock grew similarly to URGN’s over the last 12 months.

SLDB's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for URGN (100). This means that SLDB’s stock grew significantly faster than URGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SLDBURGN
RSI
ODDS (%)
N/A
Bullish Trend 13 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 13 days ago
88%
Bullish Trend 13 days ago
82%
Momentum
ODDS (%)
Bullish Trend 13 days ago
80%
Bearish Trend 13 days ago
86%
MACD
ODDS (%)
Bullish Trend 13 days ago
75%
Bearish Trend 13 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 13 days ago
81%
Bearish Trend 13 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 13 days ago
90%
Bearish Trend 13 days ago
88%
Advances
ODDS (%)
Bullish Trend 13 days ago
79%
Bullish Trend about 1 month ago
82%
Declines
ODDS (%)
Bearish Trend 27 days ago
90%
Bearish Trend 19 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 13 days ago
89%
Bullish Trend 13 days ago
88%
Aroon
ODDS (%)
Bearish Trend 13 days ago
90%
Bullish Trend 13 days ago
70%
View a ticker or compare two or three
Interact to see
Advertisement
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

SLDB and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLDB has been loosely correlated with NTLA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SLDB jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLDB
1D Price
Change %
SLDB100%
+7.24%
NTLA - SLDB
48%
Loosely correlated
+3.59%
ALLO - SLDB
47%
Loosely correlated
+5.56%
EDIT - SLDB
47%
Loosely correlated
+13.33%
BEAM - SLDB
46%
Loosely correlated
-0.88%
CRSP - SLDB
44%
Loosely correlated
-0.92%
More

URGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, URGN has been loosely correlated with MREO. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if URGN jumps, then MREO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To URGN
1D Price
Change %
URGN100%
+3.05%
MREO - URGN
47%
Loosely correlated
+0.46%
RVMD - URGN
43%
Loosely correlated
+2.04%
IMNM - URGN
39%
Loosely correlated
+0.35%
BEAM - URGN
39%
Loosely correlated
-0.88%
SLDB - URGN
38%
Loosely correlated
+7.24%
More